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Clinical Investigation

Comparative effectiveness, safety, and
costs of rivaroxaban and warfarin
among morbidly obese patients with
atrial fibrillation
Eric D. Peterson, MD, MPH, a Veronica Ashton, MPH, b Yen-Wen Chen, PhD, b Bingcao Wu, MS, b and
Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC c Durham, NC; Titusville, NJ; and Manhasset, NY

Background There are limited data regarding clinical outcomes and healthcare resource utilization of direct oral
anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are morbidly obese (body mass index N40 kg/m 2 or body
weight N120 kg).
Methods Using data from 2 US healthcare claims databases, we identified patients initiating rivaroxaban or warfarin
who had ≥1 medical claim with an AF diagnosis, a diagnostic code for morbid obesity (ICD-9: 278.01, V85.4%; ICD-10:
E66.01%, E66.2%, Z68.4%), and a minimum continuous enrollment of 12 months before and 3 months after treatment
initiation. Patients were excluded if they had mitral stenosis, a mechanical heart valve procedure, an organ/tissue transplant,
or an oral anticoagulant prescription prior to the index date. Rivaroxaban and warfarin patients were 1:1 propensity score
matched. Conditional logistic regression was used to compare ischemic stroke/systemic embolism and major bleeding risk.
Generalized linear models were used to compare healthcare resource utilization and costs.
Results A total of 3563 matched pairs of morbidly obese AF patients treated with rivaroxaban or warfarin were identified. The
majority (81.4%) of patients in the rivaroxaban cohort were receiving the 20 mg dose. The rivaroxaban and warfarin cohorts were
well balanced after propensity score matching. The risks of ischemic stroke/systemic embolism and major bleeding were similar for
rivaroxaban and warfarin users (stroke/systemic embolism: 1.5% vs 1.7%; odds ratio [OR]: 0.88; 95% confidence interval [CI]:
0.60, 1.28; P = .5028; major bleeding: 2.2% vs 2.7%; OR: 0.80; 95% CI: 0.59, 1.08; P = .1447). Total healthcare costs
including medication costs per patient per year (PPPY) were significantly lower with rivaroxaban versus warfarin ($48,552 vs
$52,418; P = .0025), which was primarily driven by lower hospitalization rate (50.2% vs 54.1%; P = .0008), shorter length of stay
(7.5 vs 9.1 days; P = .0010), and less outpatient service utilization (86 vs 115 visits PPPY; P b .0001).
Conclusions Morbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism
and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs. (Am Heart J 2019;212:113-9.)

Obesity and morbid obesity are associated with a
higher risk of developing atrial fibrillation (AF). 1,2 Among
obese patients, AF may be more severe and more
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persistent. 3,4 The standard of care for long-term prevention of embolic events in patients with AF is oral
anticoagulation. 5 Warfarin and newer direct-acting oral
anticoagulants (DOACs), such as rivaroxaban, have been
shown to significantly reduce the risk of stroke in patients
with AF. 6,7 Rivaroxaban has also been associated with a
reduction in intracranial hemorrhage compared with
warfarin. 7
Pharmacokinetic parameters, including volume of distribution, half-life, and clearance, can be altered in obese
patients, raising concerns about the potential effects of
obesity on anticoagulant activity. 8-10 Compared with patients with normal body weight, obese and morbidly obese
patients receiving warfarin had a decreased initial response
and longer time to achieve therapeutic international
normalized ratio (INR) values (8 and 10 days, respectively,
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vs 6 days). 10,11 In a study of healthy volunteers, body weight
N120 kg did not affect the peak concentration, distribution,
or half-life of rivaroxaban, and no dosage adjustment is
indicated for this population in the product labeling. 10,12,13
Population pharmacokinetic and pharmacodynamic studies
also indicate that high body weight does not have a clinically
meaningful impact on rivaroxaban pharmacology. 9 Unfortunately, no randomized controlled trials of DOACs have
been conducted in large numbers of obese patients to
determine the clinical effects of obesity on anticoagulant
efficacy and safety; however, subgroup analyses of data from
large phase 3 DOAC clinical trials suggest that the drugs are
safe and efficacious in obese patients. 14,15
In 2016, the Scientific and Standardization Committee
(SSC) of the International Society of Thrombosis and
Haemostasis (ISTH) reviewed the available data on DOAC
use in obese patients and provided several guidance
statements. 8 The committee concluded that DOACs are
safe and effective in obese patients with body mass index
(BMI) ≤40 kg/m 2 or body weight ≤120 kg; however,
limited data were available for patients with morbid
obesity (BMI N40 kg/m 2 or body weight N120 kg), and the
committee suggested that DOACs not be used in this
population because of the potential for decreased drug
exposures, reduced peak concentrations, and shorter
half-lives, leading to potential underdosing. If DOACs are
used in morbid obesity, specific pharmacokinetic monitoring was suggested, including anti-FXa for apixaban,
edoxaban, and rivaroxaban; ecarin clotting time or dilute
thrombin time with appropriate calibrators for dabigatran; or mass spectrometry drug level for any of the
DOACs.
There is a need for studies that specifically examine
outcomes of anticoagulation therapy among morbidly
obese patients. Thus, to understand the impact of morbid
obesity on real-world outcomes of anticoagulation among
AF patients, US healthcare claims data were analyzed to
compare the effectiveness, safety, and healthcare resource utilization and costs of a DOAC (rivaroxaban) and
warfarin in this population.

Materials and methods
Study design
This retrospective cohort study combined data from the
Truven MarketScan Commercial Claims and Encounters and
Medicare Supplemental databases from December 1, 2010 to
December 31, 2016. The MarketScan Commercial Claims
and Encounters database includes approximately 138 million
unique de-identified persons insured by employer-sponsored
plans. The database contains inpatient admission records,
outpatient services, prescription drugs, enrollment status,
and costs of medical services and drugs. The Medicare
Supplemental database includes health claims for Medicareeligible active and retired employees and their dependents
from employer-sponsored supplemental plans and contains
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person-specific clinical utilization, cost, and enrollment
across inpatient, outpatient, prescription drug, and carveout services.

Study population
Adult patients were eligible if they had ≥1 pharmacy
claim for rivaroxaban or warfarin between December 1,
2011 and September 30, 2016. The first pharmacy claim
date for rivaroxaban or warfarin was the index date.
Patients were also required to have: (1) ≥1 medical
claim with an AF diagnosis (International Classification
of Diseases, Ninth Revision [ICD-9]: 427.31; ICD,
Tenth Revision [ICD-10]: I48.0%, I48.2%, I48.91%) during
the 12 months prior to or on the index data, (2) a minimum
continuous health plan enrollment period of 12 months
before and 3 months following the index date, and (3) ≥1
diagnosis of morbid obesity based on ICD-9/10 codes (ICD9: 278.01, V85.4%; ICD-10: E66.01%, E66.2%, Z68.4%)
during the 12-month baseline period through 3 months
after the index date. Patients were excluded if they had
mitral stenosis (ICD-9: 394.0%, 394.2%, 396.0%, 396.1%,
746.5%, 996.02, 996.71; ICD-10: 105.0%, 105.2%, 108.0%,
134.2%, Q23.2%, T82.0%, T82.827%, T82.837%, T82.847%,
T82.857%, T82.867%, T82.897%, T82.9XX%), a mechanical
heart valve procedure (Current Procedural Terminology
[CPT]: 33405, 33420, 33422, 33425, 33426, 33427, 33430,
92987), an organ/tissue transplant (ICD-9: V42.%, V58.44;
ICD-10: Z94.%, Z48.%), or an oral anticoagulant prescription prior to the index date.
Data analysis
Demographic variables, including age, gender, and
insurance type (commercial or Medicare) were evaluated on the index date, and baseline characteristics,
including Quan-Charlson Comorbidity Index (QCI)
score, 16 individual comorbid conditions (identified via
ICD-9 or ICD-10 codes for the disease condition of
interest; see Supplemental Table I), and medication use,
were measured during the 12-month baseline period. The
modified CHA2DS2-VASc and HAS-BLED scores were measured at baseline to provide information about the risks of
stroke and major bleeding in the patient cohorts. Modifications to estimate the CHA2DS2-VASc score using the available
claims data included the presence of a diagnosis code for the
comorbid conditions of congestive heart failure, hypertension, diabetes mellitus, prior stroke, transient ischemic
attack, or vascular disease and/or prescription claims for
antihypertensive, diuretic, and antidiabetic medications. 17 A
modified HAS-BLED score of ≥3 indicated a high risk of
major bleeding. 18 The frequency and proportion of patients
who had ≥1 prescription medication and mean (standard
deviation [SD]) number of different pharmacy prescriptions
used also were reported.
All-cause healthcare resource utilization and costs
incurred during the 12-month baseline period and
follow-up period were reported for each treatment
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Table I. Demographic and baseline characteristics
Prior to matching

Characteristic
Age, years, mean (SD)
Gender, n (%)
Male
Female
Insurance type, n (%)
Commercial only
Medicare
Risk score, mean (SD)
Modified CHA2DS2-VASc score
Modified HAS-BLED score
QCI, mean (SD)
Most common comorbid conditions (N10%) †, n (%)
Hypertension
Hyperlipidemia
Diabetes
Congestive heart failure
Peripheral vascular disease
Chronic kidney disease
Number of different pharmacy prescriptions, mean (SD)
Patients with ≥1 inpatient hospitalization at baseline, n (%)

Post matching

Rivaroxaban
(n = 4543)

Warfarin
(n = 4931)

Rivaroxaban
(n = 3563)

Warfarin
(n = 3563)

Standard difference*

61.8 (10.8)

64.4 (10.8)

62.97 (10.8)

62.89 (10.6)

0.7%

2497 (55.0)
2046 (45.0)

2605 (52.8)
2326 (47.2)

1921 (53.9)
1642 (46.1)

1925 (54.0)
1638 (46.0)

0.2%
0.2%

2979 (65.6)
1564 (34.4)

2662 (54.0)
2269 (46.0)

2168 (60.8)
1395 (39.2)

2166 (60.8)
1397 (39.2)

0.1%
0.1%

3.21 (1.79)
2.25 (1.38)
1.80 (2.00)

3.85 (1.92)
2.75 (1.57)
2.60 (2.34)

3.43 (1.86)
2.40 (1.44)
2.07 (2.10)

3.43 (1.76)
2.41 (1.43)
2.09 (2.09)

0.0%
0.7%
1.0%

3962
2776
2168
1397
616
543
11.83
3448

(87.2)
(61.1)
(47.7)
(30.8)
(13.6)
(12.0)
(7.15)
(75.9)

4348
3107
2841
2218
1041
1272
12.46
4140

(88.2)
(63.0)
(57.6)
(45.0)
(21.1)
(25.8)
(7.44)
(84.0)

3091
2187
1832
1297
566
535
11.94
2853

(86.8)
(61.4)
(51.4)
(36.4)
(15.9)
(15.0)
(7.28)
(80.1)

3103
2165
1848
1299
555
538
11.98
2861

(87.1)
(60.8)
(51.9)
(36.5)
(15.6)
(15.1)
(7.31)
(80.3)

1.0%
1.3%
0.9%
0.1%
0.8%
0.2%
0.5%
0.6%

QCI, Quan-Charlson comorbidity index; SD, standard deviation.
* A standard difference ≥10% was considered significant.
†
Individual comorbid conditions were identified via ICD-9 or ICD-10 codes for the disease condition of interest, as described in Supplemental Table I.

cohort. All-cause healthcare resource utilization included
the frequency and proportion of patients who had ≥1
visit and the mean (SD) number of visits for inpatient
hospitalization (including mean [SD] length of stay),
emergency room (ER), physician office, outpatient
services, skilled nursing facility (SNF), and pharmacy
prescription(s). All costs were inflated to 2016 US dollars
and reported as total medical cost (ie, costs for inpatient
hospitalization, ER, physician office, outpatient services,
and SNF/long-term care), and total pharmacy prescription
cost. The mean number of INR measurements per patient
per year (PPPY) was identified based on CPT code 85610
during the follow-up period and was reported for the
warfarin cohort to evaluate whether warfarin patients
were being routinely monitored. Limited data on anti-FXa
measurement were available in the databases (0.3% of
rivaroxaban patients had an anti-FXa test); thus, no
analysis of the measurement of rivaroxaban's anticoagulant activity using anti-FXa was conducted.

Statistical analysis
Comparable rivaroxaban and warfarin cohorts were
created at a 1:1 ratio using propensity score-matching
techniques. A logistic regression model calculated
propensity scores for each patient based on independent
variables (Supplemental Table I) of demographic and
baseline characteristics and a dependent variable of
whether the patient initiated rivaroxaban or warfarin

treatment. The primary outcome compared between
treatment cohorts was the composite risk of ischemic
stroke and systemic embolism, calculated as the proportion of patients with an ischemic stroke and systemic
embolism (defined as hospitalization or ER visit with a
primary diagnosis of ischemic stroke and systemic
embolism, respectively, during the follow-up period)
divided by the total number of patients in the treatment
cohort. The mean (SD) number of ischemic stroke/
systemic embolism events PPPY and the time to first
event (from index date to first event during follow-up)
were determined. Secondary outcomes included major
bleeding risk, healthcare resource utilization, and costs. A
major bleeding event was defined using a validated
claims-based algorithm 19 during the follow-up period,
and risk, number of events, and time-to-event measures
were calculated as per the primary outcome. Multivariable regression models compared outcomes between
propensity score–matched treatment cohorts. Odds
ratios (OR), 95% confidence intervals (CI), and P values
were calculated. All statistical analyses were conducted
using SAS Enterprise Guide 7 (Cary, NC).

Funding
This study was funded by Janssen Scientific Affairs, LLC.
Programming support was provided by Kamal Kant
Mangla of Mu Sigma Business Solutions Pvt. Ltd.
(Bengaluru, India). Medical writing support was provided
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Table II. Risk of ischemic stroke/systemic embolism and major bleeding with rivaroxaban and warfarin
Rivaroxaban
(n = 3563)
Follow-up time, months, mean (SD)
Composite risk of ischemic stroke/systemic embolism †, n (%)
Number of composite events (PPPY), mean (SD)
Time to first composite event, days, mean (SD)
Risk of major bleeding ‡, n (%)
Number of major bleeding events (PPPY), mean (SD)
Time to first major bleeding event, days, mean (SD)

10.27
52
0.001
111.87
77
0.03
127.99

(2.89)
(1.5%)
(0.046)
(107.01)
(2.2)
(0.20)
(97.72)

Warfarin
(n = 3563)
10.56
59
0.002
125.90
96
0.03
147.56

(2.70)
(1.7%)
(0.048)
(105.64)
(2.7)
(0.22)
(110.65)

Estimate⁎
(95% CI)
−0.29
0.88
−0.01
0.90
0.80
−0.01
0.82

(−0.42, −0.16)
(0.60, 1.28)
(−0.02, 0.01)
(0.62, 1.30)
(0.59, 1.08)
(−0.01, 0.01)
(0.61, 1.10)

P
b.0001
.5028
.3592
.5690
.1447
.2570
.1878

CI, confidence interval; PPPY, per patient per year; SD, standard deviation.
⁎ Odds ratio, difference in means and hazard ratios were used for ischemic stroke/systemic embolism risk, risk of major bleeding, number of ischemic stroke/systemic embolism and
major bleeding events, and time to first event, respectively. Statistical comparisons are comparing rivaroxaban to warfarin (reference group).
†
An ischemic stroke event and systemic embolism event were defined as a hospitalization or emergency room visit with a primary diagnosis of ischemic stroke and systemic
embolism, respectively, during follow-up. Risk of ischemic stroke/systemic embolism was measured by estimating the proportion of at-risk patients who had ≥1 ischemic stroke/
systemic embolism event during follow-up.
‡
A major bleeding event was defined using a validated claims-based algorithm developed by Cunningham et al. Risk of major bleeding was measured by estimating the proportion
of at-risk patients who had ≥1 major bleeding event during follow-up.

by Ashley O'Dunne, PhD, of MedErgy (Yardley, PA, USA),
which was funded by Janssen Scientific Affairs, LLC
(Titusville, NJ, USA).

Results
Across the 2 databases, 267,467 adult patients met
entry criteria with ≥1 pharmacy claim for rivaroxaban
or warfarin, ≥1 medical claim for a diagnosis of AF, and
12 months of continuous plan enrollment prior to the
index date. Patients were excluded for oral anticoagulant
use between study start and index date (n = 144,340) and
for mitral stenosis, mechanical heart valve procedure, or
transplants (n = 9261). Of the 103,837 with continuous
enrollment within 3 months following the index date,
morbid obesity was present in 9474 (9%) patients.
Demographic and baseline characteristics for patients
before propensity score matching are shown in Table I.
The majority (81.4%) of patients in the rivaroxaban
cohort were receiving the 20 mg dose. Patients receiving
warfarin were older, were more likely to be female, and
had higher risk scores and more comorbidities and
pharmacy prescriptions compared with those receiving
rivaroxaban. Significant differences between treatment
cohorts were found for all characteristics, except the
presence of hypertension and hyperlipidemia. Propensity
score matching was successful for 3563 matched pairs
of patients with AF and morbid obesity who
initiated treatment with either rivaroxaban or warfarin
(Table I). The mean follow-up time was 10.3 months and
10.6 months for rivaroxaban and warfarin, respectively.
The composite risk of ischemic stroke and systemic
embolism was not significantly different between patients receiving rivaroxaban (1.5%) and those receiving
warfarin (1.7%; OR: 0.88, 95% CI: 0.60, 1.28; P = .5028;
Table II). The number of ischemic stroke/systemic
embolism events PPPY was also similar between groups
(rivaroxaban, 0.001; warfarin, 0.002; P = .3592). The time

to first composite event was 111.9 days with rivaroxaban
compared with 125.9 days with warfarin, a difference
that was not significant (P = .5690).
Similarly, the risk of major bleeding was not significantly different between treatment cohorts (rivaroxaban,
2.2%; warfarin, 2.7%, OR: 0.80, 95% CI: 0.59, 1.08; P =
.1447; Table II). The number of major bleeding events
was the same for both groups (0.03; P = .2570) and the
time to first event was 128.0 days for rivaroxaban and
147.6 days for warfarin (P = .1878).
Despite similar effectiveness and safety, rivaroxaban
patients had an average of $3890 lower total healthcare
costs PPPY than warfarin patients ($48,552 vs $52,418,
95% CI: –$6260, –$1398; P = .0025; Figure 1). The
differences in cost were mainly driven by a lower
hospitalization rate (50.2% vs 54.1%, OR: 0.85, 95% CI:
0.78, 0.94; P = .0008), shorter length of stay (7.5 vs 9.1
days, difference in mean: –1.61, 95% CI: –2.57, −0.65; P =
.0010), and less outpatient service utilization (86 vs 115 visits,
difference in mean: –28.81, 95% CI: –32.06, –25.43; P b
.0001) PPPY with rivaroxaban compared with warfarin,
respectively (Table III). The average number of INR events
PPPY for warfarin users was 11 (SD, 11.4).

Discussion
The results of this study indicate that AF patients with
morbid obesity initiating rivaroxaban or warfarin had
similar risks of ischemic stroke/systemic embolism and
major bleeding in clinical practice. These results are
consistent with the ROCKET-AF clinical trial findings that
demonstrated comparable efficacy and safety of rivaroxaban versus warfarin in patients with diverse body
weights. 7 In the current database analysis, risks of
stroke/systemic embolism (1.5% and 1.7%) and major
bleeding (2.2% and 2.7%) were slightly lower than those
reported in the clinical trial. Interestingly, a lower risk of
stroke and mortality has been observed with increasing
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Figure 1

A
$60,000

–$3890
P = .0025
$52,418

–$6247
P < .0001

$50,000

$48,552

Mean all-cause cost (PPPY)

$46,385

$40,000

$40,138

$30,000

$20,000
$2371
P < .0001

$10,000

$8414
$6033

$0
Total medical cost

Total pharmacy cost

B

Rivaroxaban

Total cost

Warfarin

$30,000
–$3209
P = .0211

Mean all-cause cost (PPPY)

$25,000

$24,635

$21,426

–$2444
P < .0001

$20,000
$18,226
$15,788

$15,000

$10,000

$5000

–$277
P < .0001

–$92
P = .09
$899

$1688

$991

–$230
P < .0001

$1965

$338 $568

$0
Inpatient
hospitalization

ER

Physician
office
Rivaroxaban

Outpatient
service

SNF/long-term
care

Warfarin

All-cause costs (PPPY) for A) total medical and pharmacy expenditures and B) individual components of medical costs associated with rivaroxaban
and warfarin use in morbidly obese patients with AF. AF, atrial fibrillation; ER, emergency room; PPPY, per patient per year; SNF, skilled nursing
facility.

BMI in AF patients. 14 This “obesity paradox” was most
evident in cohorts from randomized controlled trials. 15
Lower mortality rates with increasing BMI category were
also observed in the GARFIELD AF registry and the
ORBIT-AF registry. 4,20 Proietti and colleagues also
reviewed the obesity paradox data in AF patients and

found that the difference in adverse outcomes, stroke or
systemic embolic event, was not apparent in observational studies after statistical adjustment for associated
comorbidities in obese patients because of more intense
risk factor management and improved outcomes. 14 Our
data suggest that morbidly obese patients with AF who
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Table III. Healthcare resource utilization and length of stay associated with rivaroxaban and warfarin use in morbidly obese patients with AF
AF patients
Rivaroxaban
(n = 3563)
All-cause healthcare resource utilization
Patients with ≥1 event of interest, n (%)
Inpatient hospitalization
ER visit
Office visit
Outpatient visit
SNF/long-term care
Number of events of interest (PPPY), mean (SD)
Inpatient hospitalization
ER visit
Office visit
Outpatient visit
Pharmacy fill
Length of hospital stay, mean (SD)
Among all patients
Among patients with ≥1 hospitalization

1787
1011
3484
3549
286

(50.2)
(28.4)
(97.8)
(99.6)
(8.0)

1.48
0.52
15.50
86.01
60.73

(2.76)
(1.12)
(10.87)
(78.53)
(36.35)

7.45 (19.52)
14.85 (25.49)

Warfarin
(n = 3563)

1929
1149
3485
3547
344
1.90
0.63
19.21
114.82
64.14

(54.1)
(32.2)
(97.8)
(99.6)
(9.7)
(3.81)
(1.53)
(14.03)
(130.66)
(37.83)

9.06 (21.76)
16.74 (27.32)

Estimate⁎ (95% CI)

0.85
0.83
0.99
1.14
0.81
−0.41
−0.11
–3.72
−28.81
−3.42

(0.78,
(0.75,
(0.72,
(0.56,
(0.68,

P

0.94)
0.92)
1.36)
2.34)
0.96)

.0008
.0004
.9351
.7152
.0131

(−0.52, −0.29)
(−0.16, −0.06)
(−4.21, −3.21)
(−32.06, −25.43)
(−4.99, −1.81)

b.0001
.0001
b.0001
b.0001
b.0001

−1.61 (−2.57, −0.65)
−1.88 (−3.59, −0.18)

.0010
.0302

AF, atrial fibrillation; CI, confidence interval; ER, emergency room; PPPY, per patient per year; SD, standard deviation; SNF, skilled nursing facility.
⁎ Odds ratio was used for categorical variables, and difference in means was used for continuous variables.

were matched for comorbidities and underlying risks can
achieve similarly effective anticoagulation with rivaroxaban as with warfarin. These data are valuable because
they provide real-world outcomes for the morbidly obese
population with AF.
While providing similar effectiveness and safety, treatment with rivaroxaban was associated with significantly
lower healthcare resource utilization and costs than
warfarin in this patient population. Routine monitoring of
the anticoagulant effect of rivaroxaban using specialized
coagulation assays, such as anti-FXa, was not routinely
done, which may contribute to the large difference in
outpatient visits between treatment groups. Patients
receiving warfarin had an average of 11 claims annually
for INR monitoring. This nearly monthly INR monitoring is
consistent with the frequency of INR monitoring found in
real-world practice settings for warfarin monitoring. 21
In addition to fewer outpatient visits, rivaroxaban
treatment also resulted in a significantly lower hospitalization rate and shorter length of hospital stay. Laliberté and
colleagues compared healthcare costs between AF patients
regardless of body weight or BMI using rivaroxaban and a
matched sample of patients using warfarin and found that
(similar to results of the current study in morbidly obese AF
patients) all-cause hospitalization and outpatient costs were
significantly lower for AF patients treated with rivaroxaban
compared to those treated with warfarin. 22 Treatment
with rivaroxaban appears to result in less interaction with
healthcare systems, either on an inpatient or outpatient
basis, 22 which is consistent with the current study findings.
This study has several strengths, including the availability
of a large dataset of obese patients with geographically

diverse claims data to increase the generalizability of the
data and its analyses. Propensity score matching reduced
selection biases from measured confounders, such as
comorbidities, and improved the internal validity of the
estimates. At least 15 months of continuous health plan
enrollment in this retrospective study enabled researchers
to better understand the population characteristics and
longitudinally evaluate outcomes during the follow-up
period without interruption. Study limitations include the
use of administrative claims data that, in general, are
subject to potential coding errors and inconsistencies. The
presence of a claim for a dispensed prescription does not
indicate that the medication was consumed or that it was
taken as prescribed. Also, the use of diagnosis codes to
identify obesity may underestimate this patient population,
as height and weight are not available in claims data to
confirm BMI status. Martin and colleagues assessed the
validity of obesity coding in an administrative database and
found substantial underreporting. 23 However, once obesity was coded, it was done accurately and could be used to
identify a cohort for follow-up or outcomes studies. 23 The
addition of height and body weight information into
routine administrative data coding could eliminate inconsistencies between clinician observation and patient
reporting and improve data resources for populationbased studies. 23
These real-world data add to the clinical and pharmacologic data supporting the use of rivaroxaban in
morbidly obese patients with AF. The risks of ischemic
stroke/systemic embolism and major bleeding were
comparable with rivaroxaban and warfarin in this patient
population. In addition to similar outcomes, healthcare
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costs were significantly lower with rivaroxaban as a result
of fewer inpatient and outpatient visits compared with
warfarin.
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ahj.2019.02.001.

Acknowledgements
The authors acknowledge Kamal Kant Mangla of Mu
Sigma Business Solutions Pvt. Ltd. (Bengaluru, India) for
providing programming support. Medical writing support was provided by Ashley O'Dunne, PhD, of MedErgy
(Yardley, PA, USA), which was funded by Janssen
Scientific Affairs, LLC (Titusville, NJ, USA).

Declaration of interests
E. D. Peterson: Consultant/Advisory Board; Janssen
Scientific Affairs, LLC.
V. Ashton: Employment; Janssen Scientific Affairs, LLC.
Y. Chen: Employment; Janssen Scientific Affairs, LLC.
B. Wu: Employment; Janssen Scientific Affairs, LLC.
A. C. Spyropoulos: Consultant/Advisory Board; Janssen
Scientific Affairs, LLC.

Funding source
This study was funded by Janssen Scientific Affairs, LLC.

Previous Presentation
Presented at the American Heart Association Scientific
Sessions, November 10–12, 2018.

References
1. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset
atrial fibrillation. JAMA 2004;292:2471-7.
2. Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, postoperative, and post-ablation atrial fibrillation: a meta-analysis of 626,603
individuals in 51 studies. JACC Clin Electrophysiol 2015;1:139-52.
3. Nalliah CJ, Sanders P, Kottkamp H, et al. The role of obesity in atrial
fibrillation. Eur Heart J 2016;37:1565-72.
4. Pandey A, Gersh BJ, McGuire DK, et al. Association of body mass index
with care and outcomes in patients with atrial fibrillation: results from the
ORBIT-AF Registry. JACC Clin Electrophysiol 2016;2:355-63.
5. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS
guideline for the management of patients with atrial fibrillation: a
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and the Heart Rhythm.
J Am Coll Cardiol 2014;64:2246-80.
6. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the
prevention of stroke associated with nonrheumatic atrial fibrillation.
Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation
Investigators. N Engl J Med 1992;327:1406-12.

Peterson et al 119

7. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus
warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:
883-91.
8. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct
oral anticoagulants in obese patients: guidance from the SSC of the
ISTH. J Thromb Haemost 2016;14:1308-13.
9. Moore KT, Kroll D. Influences of obesity and bariatric surgery on the
clinical and pharmacologic profile of rivaroxaban. Am J Med
2017;130:1024-32.
10. Domienik-Karłowicz J, Pruszczyk P. The use of anticoagulants in
morbidly obese patients. Cardiol J 2016;23:12-6.
11. Wallace JL, Reaves AB, Tolley EA, et al. Comparison of initial
warfarin response in obese patients versus non-obese patients.
J Thromb Thrombolysis 2013;36:96-101.
12. Xarelto® (rivaroxaban) tablets, for oral use. Prescribing information.
Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017.
13. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited
influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin
Pharmacol 2007;47:218-26.
14. Proietti M, Guiducci E, Cheli P, et al. Is there an obesity paradox for
outcomes in atrial fibrillation? A systematic review and meta-analysis
of non-vitamin K antagonist oral anticoagulant trials. Stroke 2017;48:
857-66.
15. Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of risk of stroke in
patients with atrial fibrillation to body mass index (from patients
treated with rivaroxaban and rarfarin in the rivaroxaban once daily
oral direct factor Xa inhibition compared with vitamin K antagonism
for prevention of stroke and embolism trial in atrial fibrillation trial).
Am J Cardiol 2017;119:1989-96.
16. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson
comorbidity index and score for risk adjustment in hospital discharge
abstracts using data from 6 countries. Am J Epidemiol 2011;173:
676-82.
17. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification
for predicting stroke and thromboembolism in atrial fibrillation using
a novel risk factor-based approach: the euro heart survey on atrial
fibrillation. Chest 2010;137:263-72.
18. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score
(HAS-BLED) to assess 1-year risk of major bleeding in patients with
atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
19. Cunningham A, Stein CM, Chung CP, et al. An automated database
case definition for serious bleeding related to oral anticoagulant use.
Pharmacoepidemiol Drug Saf 2011;20:560-6.
20. Goldhaber SZ, Bassand J-P, Accetta G. Impact of body mass index in
newly diagnosed atrial fibrillation in the GARFIELD-AF registry.
Presented at the European Society of Cardiology Congress,
Barcelona, Spain; 26-30 August 2017. P87116; 2017.
21. Barnes GD, Misirliyan S, Kaatz S, et al. Barriers and facilitators to
reducing frequent laboratory testing for patients who are stable on
warfarin: a mixed methods study of de-implementation in five
anticoagulation clinics. Implement Sci 2017;12:87.
22. Laliberte F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus
warfarin on health care costs among nonvalvular atrial fibrillation
patients: observations from rivaroxaban users and matched warfarin
users. Adv Ther 2015;32:216-27.
23. Martin B-J, Chen G, Graham M, et al. Coding of obesity in
administrative hospital discharge abstract data: accuracy and impact
for future research studies. BMC Health Serv Res 2014;14:70.

